John Otrompke, BA, JD

psoriatic arthritis elbow
Conference Coverage
Safety Profile in Patients With Psoriatic Arthritis Treated With Risankizumab Similar to That in Patients With Plaque Psoriasis
03/26/2022
The scientists analyzed data from 17 phase 1–3 clinical trials in psoriasis and 4 phase 2/3 trials in psoriatic arthritis.
The scientists analyzed data from 17 phase 1–3 clinical trials in psoriasis and 4 phase 2/3 trials in psoriatic arthritis.
The scientists analyzed data...
03/26/2022
The Dermatologist
News
Polatuzumab Vedotin Improves PFS in Previously Untreated DLBCL
05/03/2022
A modified regimen of R-CHOP in which vincristine is replaced with polatuzumab vedotin yielded lower risk of disease progression, relapse, or death among patients with previously untreated intermediate-risk or high-risk DLBCL.
A modified regimen of R-CHOP in which vincristine is replaced with polatuzumab vedotin yielded lower risk of disease progression, relapse, or death among patients with previously untreated intermediate-risk or high-risk DLBCL.
A modified regimen of R-CHOP in...
05/03/2022
Oncology
News
Beta Blockers Provide No Prognostic Value Among Patients With Resected, High-Risk Melanoma
06/02/2022
Study findings suggest beta blockers provide no prognostic effect on recurrence-free survival among patients with resected, high-risk melanoma in the KEYNOTE-054 trial.
Study findings suggest beta blockers provide no prognostic effect on recurrence-free survival among patients with resected, high-risk melanoma in the KEYNOTE-054 trial.
Study findings suggest beta...
06/02/2022
Oncology
News
Rucaparib Provides PFS Benefit vs Chemotherapy for BRCA1– or BRCA2–Mutant Ovarian Cancer
04/14/2022
Among patients with BRCA1– or BRCA2–mutant ovarian carcinoma, treatment with rucaparib was associated with improved PFS vs standard chemotherapy in the phase 3 ARIEL4 trial.
Among patients with BRCA1– or BRCA2–mutant ovarian carcinoma, treatment with rucaparib was associated with improved PFS vs standard chemotherapy in the phase 3 ARIEL4 trial.
Among patients with BRCA1– or...
04/14/2022
Oncology
News
Atezolizumab Added to Neoadjuvant Chemotherapy in Triple–Negative Breast Cancer: NeoTRIP Study
05/11/2022
Atezolizumab added to neoadjuvant chemotherapy did not significantly improve the rate of pathological complete response in triple–negative breast cancer, according to an analysis from the ongoing NeoTRIP Michelangelo trial.
Atezolizumab added to neoadjuvant chemotherapy did not significantly improve the rate of pathological complete response in triple–negative breast cancer, according to an analysis from the ongoing NeoTRIP Michelangelo trial.
Atezolizumab added to...
05/11/2022
Oncology
News
Study Highlights Need for New Treatment Approaches, Novel Therapies for Relapsed/Refractory MM
05/11/2022
Findings from the LocoMMotion study demonstrate there is no well-established standard of care treatment for patients with triple-class exposed relapsed/refractory MM.
Findings from the LocoMMotion study demonstrate there is no well-established standard of care treatment for patients with triple-class exposed relapsed/refractory MM.
Findings from the LocoMMotion...
05/11/2022
Oncology
News
Optimal Period of ADT May Vary Depending on Receipt of Brachytherapy in High-Risk Prostate Cancer
03/30/2022
The optimal minimum duration of ADT may be less than 18 months for high-risk prostate cancer patients receiving external beam radiation therapy (EBRT) plus brachytherapy, but more than 18 months for patients receiving EBRT alone.
The optimal minimum duration of ADT may be less than 18 months for high-risk prostate cancer patients receiving external beam radiation therapy (EBRT) plus brachytherapy, but more than 18 months for patients receiving EBRT alone.
The optimal minimum duration of...
03/30/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Second-Line Cemiplimab Yields Benefit in Improved OS vs Chemotherapy in Cervical Cancer
03/30/2022
Treatment of cervical cancer patients who had disease progression after first-line platinum-containing chemotherapy with the programmed cell death 1 (PD-L1)-blocking antibody cemiplimab was associated with statistically significantly improved...
Treatment of cervical cancer patients who had disease progression after first-line platinum-containing chemotherapy with the programmed cell death 1 (PD-L1)-blocking antibody cemiplimab was associated with statistically significantly improved...
Treatment of cervical cancer...
03/30/2022
Oncology
News
Homoharringtonine Shows Promising Efficacy for Patients With AML
03/21/2022
Homoharringtonine may be added to idarubicin and cytarabine to induce remission for patients with newly diagnosed AML.
Homoharringtonine may be added to idarubicin and cytarabine to induce remission for patients with newly diagnosed AML.
Homoharringtonine may be added...
03/21/2022
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use